Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer

• References

• 1 Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
• 2 Druker BJ, Talpaz M, Resta DJ. et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
• 3 Song KW, Rifkind J, Al-Beirouti B. et al. Subdural hematoma during CML therapy with imatinib mesylate. Leuk Lymph 2004; 45: 1633-1636.
• 4 Radaeli F, Vener C, Ripamonti F. et al. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol 2007; 86: 390-393.
• 5 Larson RA, Druker BJ, Guilhot F. et al. Imatinib pharmacokinetics and its correlation with @response and safety in chronic-phase chronic myeloid leukemia:subsequent analysis of the IRIS study. Blood 2008; 111: 4022-4028.
• 6 Matsue K, Aoki T, Odawara J. et al. Hemorrhagic complications during the use of imatinib associated with the decrease of alpha2-plasmin inhibitor in a atient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukmia Res 2009; 33: 860-869.
• 7 Matsuda T, Ogawa M. Selective determination of plasmin inhibitor activity in plasma using chromogenic substrate. Thrombos Res 1984; 33: 379.
• 8 Kluft C, Vellenga E, Brommer EJP. et al. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of α2-antiplasmin. Blood 1982; 59: 1169-1180.
• 9 Favier R, Aoki N, de Moerloose P. Congenital α2-plasmin inhibitor deficiency: a review. Br J Haematol 2001; 114: 4-10.
• 10 Hersch SL, Kunelis T, Francis Jr RB. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987; 69: 1315-1319.
• 11 Legros L, Bourcier C. Jacquel, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma cencentration in patients with chronic myeloid leukemia. Blood 2004; 104: 495-501.
• 12 Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New Engl J Med 2005; 353: 172-187.
• 13 Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. New Engl J Med 2008; 359: 1261-1270.
• 14 Matsuno H, Ishisaki A, Nakajima K. et al. Lack of α2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. Blood 2003; 102: 33621-33628.
• 15 Matsuno H. α2-antiplasmin on cardiovascular diseases. Curr Pharmaceut Des 2006; 12: 841-847.